SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported) January 10, 2018
(Exact name of registrant as specified in
(State or other jurisdiction of incorporation)
|(Commission File Number)
||(IRS Employer Identification No.)|
|3950 South Country Club, Suite 470, Tucson, Arizona
|(Address of principal executive offices)
(Registrant’s telephone number, including
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|o||Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|o||Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|o||Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|o||Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. o
|Item 2.02||Results of Operations and Financial Condition.
On January 10, 2018, Accelerate Diagnostics,
Inc. (the “Company”) issued a press release (the “Press Release”) announcing certain preliminary financial
results for the quarter ending December 31, 2017. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference in its entirety.
In accordance with General Instruction B.2
for Form 8-K, the information in this Item 2.02, including the related information contained in Exhibit 99.1, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
In addition to the
disclosure described above under Item 2.02 of this Current Report on Form 8-K, the Press Release also announced the Company’s
declaration of conformity to the European In Vitro Diagnostic Directive 98/79/EC and CE mark of its latest assay for the
Accelerate Pheno™ system targeting severe bacterial pneumonia infections. A copy of the Press Release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference in its entirety.
|Item 9.01 ||Financial
Statements and Exhibits.
(d) Exhibits. The
following materials are filed as exhibits to this Current Report on Form 8-K:
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 10, 2018
ACCELERATE DIAGNOSTICS, INC.
/s/ Steve Reichling
Chief Financial Officer